Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2006 Dec;50(12):4214-6. Epub 2006 Oct 2.

Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis.

Author information

1
Laboratorio de Bioquímica y Biología Molecular de Parásitos, Instituto de Biología Experimental, Facultad de Ciencias, Universidad Central de Venezuela, Apartado 47577, Caracas 1041A, Venezuela.

Abstract

Glibenclamide reduced the rate of lesion growth in BALB/c mice infected with Leishmania (Leishmania) mexicana, the effect was dose dependent, and the highest dose proved more effective than glucantime. Cross-resistance to glucantime was found in animals infected with a glibenclamide-resistant line, but combined therapy reduced lesion progression even in the glibenclamide-resistant strain.

PMID:
17015627
PMCID:
PMC1693980
DOI:
10.1128/AAC.00617-06
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center